Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu

At Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu in Bucharest, clinical research focuses on urgent and high-risk cardiovascular diseases, including STEMI, atherosclerotic cardiovascular disease, and broader cardiovascular mortality prevention. These studies aim to test new treatments that may improve survival, reduce major heart events, and support faster care in emergency settings.

• Testing a new approach for patients with suspected acute myocardial infarction to improve early clinical outcomes
• Evaluating therapies designed to lower the risk of heart attack, stroke, and other major cardiovascular events
• Studying treatment strategies for people with established vascular disease and elevated cholesterol-related risk

These trials reflect strong interest in improving both immediate emergency treatment and long-term prevention of serious heart complications.

This site is also active in research on pulmonary hypertension, especially pulmonary arterial hypertension and group I PAH. The studies are designed to assess new therapies, compare treatment combinations, and follow longer-term safety and benefit in patients living with this progressive condition.

• Comparing combination treatment strategies for PAH to improve risk status and disease control
• Assessing new options intended to reduce pulmonary vascular resistance and improve heart-lung function
• Monitoring the long-term safety and tolerability of therapies for people with pulmonary arterial hypertension

Research in this area aims to improve symptoms, slow disease progression, and offer better treatment choices for patients with advanced pulmonary vascular disease.

Clinical trials at the Cardiologie 1/USTAC department include a major focus on heart failure, including chronic heart failure, HFmrEF, HFpEF, and worsening heart failure. Several studies also address the link between heart failure and kidney dysfunction, systemic inflammation, and symptom burden, with the goal of improving outcomes and quality of life.

• Testing new treatments to reduce heart failure events and cardiovascular death
• Evaluating therapies for patients with heart failure and impaired kidney function
• Studying approaches that may improve symptoms, fluid balance, and patient-reported wellbeing in worsening heart failure

These trials explore both disease-modifying therapies and supportive strategies for patients with complex, chronic cardiac conditions.

Another important research area involves cardiac surgery and clotting-related complications, including acquired antithrombin deficiency and heparin resistance. The studies are aimed at improving blood-thinning responsiveness during procedures that require cardiopulmonary bypass, where safe clot control is critical.

• Evaluating treatment options to restore heparin responsiveness in surgical patients
• Supporting safer anticoagulation management during complex heart surgery
• Investigating ways to reduce procedure-related clotting risks in high-acuity care

Research in this field is focused on helping surgical teams manage coagulation more effectively and safely in vulnerable patients.

The site also participates in studies linking type 2 diabetes, hypertension, and cardiovascular disease, as well as trials targeting inflammation in people with heart failure. These projects aim to reduce future cardiovascular events by addressing overlapping risk factors and chronic disease burden.

• Testing therapies for people with type 2 diabetes and high blood pressure who already have cardiovascular disease
• Studying treatments intended to lower heart failure risk in patients with inflammatory features
• Evaluating new options for patients with complex, multi-condition cardiovascular risk profiles

Overall, this research supports a more integrated approach to prevention, combining heart care with metabolic and inflammatory disease management.

Clinical research at this hospital/clinic facility also includes rare but serious conditions such as transthyretin amyloidosis with cardiomyopathy. These studies are designed to evaluate whether new therapies can improve survival and reduce the burden of disease in patients with this difficult-to-treat heart condition.

• Assessing treatments for ATTR cardiomyopathy to slow disease progression
• Studying whether new therapies can reduce all-cause mortality and cardiovascular complications
• Exploring options for patients with specialized, high-need cardiomyopathy care

These trials highlight the center’s involvement in both common cardiovascular disorders and more specialized rare-disease research.